source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable7 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
external sourcelocator
doi:10.1001/jama.2023.13239
doi
10.1001/jama.2023.13239
imported
2026-05-06T03:57:47.119859+00:00
extraction mode
manual_curation
journal
JAMA
authors
reviewer:will-blair-bot
Caveats
No source-specific caveats are recorded.
therapeutic · vf_092bd1220b85fda6
therapeutic · vf_7b4bfdf919b22af5
therapeutic · vf_e2554d6d7ec32686
Donanemab treatment increases ARIA risk, making benefit interpretation inseparable from imaging surveillance and patient selection.
events
vev_03ae13478d091c6dfinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_181ae8b59b4826cdfinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_6506b5c540f90552finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_89552b6ef30c80d3finding.reviewedDonanemab TRAILBLAZER-ALZ 2 (Sims et al., JAMA 2023) demonstrated 35% slowing on iADRS in low/medium tau cohort and 22% in combined cohort over 18 months. Primary endpoint positive. Agent-drafted accept; eligible for human re-review.
agent:vela-curation-bot-2026-05-09 · 2026-05-09
vev_9860367b0179abe0finding.caveatedTau-selection criteria affect generalization to broader clinical populations.
reviewer:will-blair-bot · 2026-05-06
vev_b2ed1b21631486fefinding.reviewedReviewed for decision-console use: bounded TRAILBLAZER-ALZ 2 benefit claim with trial population and biomarker-selection scope.
reviewer:will-blair-bot · 2026-05-06
vev_d7eea5ea523a177ffinding.caveatedDecision-console scope: this supports a bounded early symptomatic donanemab claim under amyloid/tau selection criteria; it does not remove the need to inspect ARIA risk, treatment discontinuation rules, and endpoint meaningfulness.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_0014e47ebf928b0afinding.reviewReviewed for decision-console use: bounded TRAILBLAZER-ALZ 2 benefit claim with trial population and biomarker-selection scope.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_0fbbede3a7e0c8effinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_1024419a835feaecfinding.reviewDonanemab TRAILBLAZER-ALZ 2 (Sims et al., JAMA 2023) demonstrated 35% slowing on iADRS in low/medium tau cohort and 22% in combined cohort over 18 months. Primary endpoint positive. Agent-drafted accept; eligible for human re-review.
applied · agent:vela-curation-bot-2026-05-09 · 2026-05-09
vpr_14efe481b72d9e44finding.caveatDecision-console scope: this supports a bounded early symptomatic donanemab claim under amyloid/tau selection criteria; it does not remove the need to inspect ARIA risk, treatment discontinuation rules, and endpoint meaningfulness.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_2ce006ffa5c100e5finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_d9ec6f23226ebc44finding.caveatTau-selection criteria affect generalization to broader clinical populations.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_f3a6eed6c7cf8978finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation rows are attached.